PAVmed is a medical device company employing a business model to bring innovative products from concept to commercialization with speed and capital efficiency, while enhancing and accelerating value creation.
PAVmed is building a deep pipeline of products encompassing a broad spectrum of clinical areas possessing attractive regulatory pathways and market opportunities currently exceeding $4 billion. The company currently has five lead products to provide multiple near-term value creation opportunities
The Company is led by a team of accomplished medical device entrepreneurs. The leadership team has previously successfully implemented its unique business model of creating value with modest capital investment in four single-product companies, each of which rapidly advanced towards commercialization. Two of these four products have been cleared and commercialized, while two products are currently undergoing FDA review. PAVmed leverages this unique business model.
By establishing a long-term multi-product company with access to public capital, the company plans to build an expanding pipeline of innovative products across a range of specialties and clinical conditions.
Featured Press Releases
3/21/17 7:30 am EDTNEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW), a highly differentiated, multi-product medical device company, today announced that it has appointed Dennis M. McGrath as its new Executive Vice President and Chief Financial Officer. Mr. McGrath brings over thirty years of corporate finance and executive experience to PAVmed, spanning both entrepreneurial and public company settings. Since 2000, Mr. McGrath has served in multiple executive leadership roles atmore...
3/9/17 7:00 am ESTNEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq:PAVM, PAVMW), a highly differentiated, multi-product medical device company, today announced the closing of approximately $1.0 million in additional financing, bringing the aggregate gross proceeds of our private placement to $2.5 million. The private placement consists of shares of Series A Convertible Preferred Stock and Series A Warrants. The initial closing was previously announced in February. Dr. Lishan Aklog,more...
2/23/17 7:00 am ESTNEW YORK--(BUSINESS WIRE)--PAVmed Inc. (Nasdaq: PAVM, PAVMW) announced today that the Company intends to effectuate a registered exchange offer (the “Exchange”) whereby PAVmed’s Common Stock will become exchangeable for units (the “New Units”). Pursuant to the Exchange, each New Unit will be comprised of one share of Common Stock, identical to the currently outstanding Common Stock, and one newly-issued warrant (the “New Unit Warrant”). Each holder ofmore...